Autologous and allogenic Natural Killer cell therapy

NKGen Biotech is focused on harnessing the potential of natural killer (NK) cells to develop innovative immunotherapies aimed at treating various diseases, including neurodegenerative disorders and cancer. Their approach involves enhancing the body’s innate immune response by utilizing super-activated NK cells, which are designed to effectively target and eliminate diseased cells. The company is currently conducting clinical trials to evaluate the safety and efficacy of their NK cell therapies, specifically the SNK01 and SNK02 therapies, which are being tested in patients with conditions such as Alzheimer’s disease and advanced solid tumors.

The science behind NKGen Biotech's therapies is rooted in the unique capabilities of NK cells, which play a crucial role in the immune system by identifying and destroying abnormal or infected cells. These cells are characterized by their ability to respond quickly to threats without the need for prior sensitization, making them a vital component of the body’s defense mechanisms. NKGen Biotech aims to restore and enhance NK cell function, particularly in patients whose immune responses may be compromised due to age or disease, thereby improving overall health outcomes and offering new treatment options for challenging medical conditions.

United States

NKGen Biotech is harnessing the power of the body's immune system through the development of unique Natural Killer (NK) cell therapies.  NK cell adoptive immunotherapy enhances a patient's ability to destroy abnormal cells. The mission of NKGen Biotech is to improve patients'​ lives in a safe and natural way through innovative cell therapy products and to ultimately become the global leader in immune cell therapeutics.

Cancer

Nervous System Diseases

NKGen Biotech

Neurodegenerative disease

Solid tumor/s

SNK01

Biologics

Cell Therapies

SNK02

Alzheimer's disease

<p class="font_8">SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug candidate. NKGen Biotech, Inc. is developing SNK01 for the treatment of neurodegenerative disorders and a broad range of cancers.</p>

NKGen Biotech

Company Details